Yahoo Finance

Operations: YiChang HEC ChangJiang Pharmaceutical generates revenue primarily from the sales of pharmaceutical products, totaling CN¥6.29 billion. The company's financial performance is influenced by its cost structure and operational efficiencies.

YiChang HEC ChangJiang Pharmaceutical has shown impressive earnings growth of 2501.2% over the past year, far outpacing the Pharmaceuticals industry average of 0.1%. The company's price-to-earnings ratio stands at a modest 3.9x compared to the Hong Kong market's 9x, indicating potential undervaluation. Interest payments on its debt are well covered by EBIT with a coverage ratio of 16.9x, and despite an increase in debt to equity from 1.5% to 30.5% over five years, its net debt to equity remains satisfactory at 9.2%.

• Click here and access our complete health analysis report to understand the dynamics of YiChang HEC ChangJiang Pharmaceutical.

• Examine YiChang HEC ChangJiang Pharmaceutical's past performance report to understand how it has performed in the past.

Sinopec Kantons Holdings

Simply Wall St Value Rating: ★★★★★★

Overview: Sinopec Kantons Holdings Limited, an investment holding company, provides crude oil jetty services and has a market cap of HK$11.34 billion.

Operations: The company's primary revenue stream comes from crude oil jetty and storage services, generating HK$609.87 million. Its financial performance is influenced by the costs associated with providing these services, impacting its net profit margin.

Sinopec Kantons Holdings, a relatively small player in Hong Kong's market, shows promising metrics. Trading at 77.3% below its estimated fair value, it boasts high-quality earnings and zero debt. Over the past year, its earnings surged by 198.6%, outpacing the Oil and Gas industry’s -6.8%. The company has also successfully reduced its debt from a 31.4% debt-to-equity ratio five years ago to none today. Recent leadership changes include Mr. Zhong Fuliang becoming Chairman as of July 2024.

• Dive into the specifics of Sinopec Kantons Holdings here with our thorough health report.

• Explore historical data to track Sinopec Kantons Holdings' performance over time in our Past section.

Where To Now?

• Unlock our comprehensive list of 173 SEHK Undiscovered Gems With Strong Fundamentals by clicking here.

• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.

• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:1277 SEHK:1558 and SEHK:934.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com